Inform your patients about Scholar Rock Supports™.  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
[Dear/Hello/Hi/Good morning/Good afternoon/Good evening/Greetings] [Dr/Doctor/Miss/Mr/Mrs/Ms] [First Name] [Last Name],
Thank you for your partnership and your patients’ commitment to the apitegromab clinical program.
ONYX Clinical Trial Information
As a follow-up to our recent conversation, as of [date], ISEMBYLD™ (apitegromab-mstn) has been approved by the US Food and Drug Administration (FDA). Per the ONYX clinical trial protocol, patients who wish to continue with ISEMBYLD treatment will need to transition to commercially available product once a path to access is determined. Patients may also need to complete an end-of-treatment visit, which will serve as their end-of-study visit, before receiving their first commercial infusion. Your Clinical Research Associate will be in touch about end-of-study/end-of-treatment protocol once insurance approval is in place.
Our priority is to ensure uninterrupted care for patients who choose to continue treatment with ISEMBYLD. We understand that insurance approval is needed before transitioning to commercial therapy, and Scholar Rock is committed to supporting you and your team throughout this process.
Next Steps: Scholar Rock Supports™ Enrollment
Enrollment in Scholar Rock Supports will enable us to help coordinate and support appropriate patients through the transition from the ONYX clinical trial. Our program can help patients with:
• Insurance access and benefits support
• Financial support and copay assistance (for eligible patients)
• Infusion day coordination (at home, in hospital, or infusion center)
• Caregiver support and resources
• Guidance on what patients can expect with treatment
The Scholar Rock Supports enrollment form must be signed by the prescriber and patient, or patient's legal representative. The patient or the patient's legal representative can review, complete, and electronically sign the patient sections of the form via the Scholar Rock eConsent portal at srrksupportsconsent.com. Once completed, it will activate support by an experienced and dedicated team including an Rx Onboarding and Care Coordinator (ROCC).
Scholar Rock Supports™ logo
I’ve attached a one-page, step-by-step patient transition guide for your reference. If you have transition questions, please contact [me/your ROCC]. To get started, please click the link below to download and print the Scholar Rock Supports enrollment form. Please read the instructions on the form for how to complete and return it via fax to 877-219-0016.
Download English Enrollment Form
Download Spanish Enrollment Form
Scholar Rock remains dedicated to supporting sites, patients, and families to ensure seamless continuity of treatment.
For any questions, please reach out to me directly. If you have ONYX protocol questions, please contact your ONYX Clinical Research Associate.
[Sincerely] [Best] [Regards],
[Rx Onboarding and Care Coordinator/Regional Clinical Specialist/Field Reimbursement Manager first name and last name]
[Rx Onboarding and Care Coordinator/Regional Clinical Specialist/Field Reimbursement Manager title]
[Rx Onboarding and Care Coordinator/Regional Clinical Specialist/Field Reimbursement Manager phone number]
[Rx Onboarding and Care Coordinator/Regional Clinical Specialist/Field Reimbursement Manager email address]
301 Binney Street, 3rd Floor
Cambridge, MA 02142
ISEMBYLD and Scholar Rock Supports are trademarks of Scholar Rock.
Scholar Rock © 2026. All rights reserved.
US-APIT-0219 09/26
This advertisement is intended only for healthcare professionals in the United States.